'Hr 95 ci 0' diaporamas de présentation

Prevention of Periop MI: Where are we now; & where are we going?

Prevention of Periop MI: Where are we now; & where are we going?. H Yang Department of Anesthesiology. Pre-op. Intra-. Post-. n. (%). op (%). op (%). Mangano. 474. 20. 25. 40. NEJM. 1990. Raby. 115. 20. 18. 30. JAMA. 1992. Perioperative Ischemia.

494 views • 40 slides

HORIZONS AMI Trial

592 views • 37 slides

HORIZONS AMI Trial

538 views • 36 slides

????? EGFR ?????????????

????? EGFR ?????????????. ? ? ?????????? ??????. IPASS Study:Progression-free survival by EGFR mutation type (ITT population). Exon 19 deletion. L858R. Gefitinib (n=66) Carboplatin/paclitaxel (n=74). Gefitinib (n=64) Carboplatin/paclitaxel (n=47). 1.0. 1.0.

730 views • 24 slides

Reverse Remodeling and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT

Reverse Remodeling and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT. Alon Barsheshet , MD 1 , Paul J. Wang, MD 2 , Arthur J. Moss, MD 1 , Scott D. Solomon, MD 3 , Amin Al-Ahmad, MD 2 , Scott McNitt , MS 1 , Elyse Foster, MD 4 ,

279 views • 20 slides

American Heart Association Scientific Sessions 2018

American Heart Association Scientific Sessions 2018. Ticagrelor for long-term secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: Insights from PEGASUS-TIMI 54.

227 views • 18 slides

The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature

The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature Manel Esteller , MD, PhD. Director, Josep Carreras Leukaemia Research Institute (IJC) Director, Cancer Epigenetics and Biology Program (PEBC) ICREA Research Professor

154 views • 15 slides